ARRHYTHMOGENIC CARDIOMYOPATHY
Clinical trials for ARRHYTHMOGENIC CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new ARRHYTHMOGENIC CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for ARRHYTHMOGENIC CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy trial hopes to fix heart muscle in rare genetic disease
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 in 10 adults with a rare, inherited heart condition (PKP2-ACM) that can cause dangerous heart rhythms and heart failure. The therapy is given once through a vein and aims to deliver a working copy of the PKP2 gene to heart…
Matched conditions: ARRHYTHMOGENIC CARDIOMYOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
Gene therapy for rare heart disease: Long-Term safety check begins
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received the experimental gene therapy LX2020 for a genetic heart condition called arrhythmogenic cardiomyopathy. Researchers will monitor them for years to see if the treatment remains safe and continues to work. The goal is to understand…
Matched conditions: ARRHYTHMOGENIC CARDIOMYOPATHY
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:43 UTC